BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35579771)

  • 21. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes.
    Chen YH; Chen SN; Lien RI; Shih CP; Chao AN; Chen KJ; Hwang YS; Wang NK; Chen YP; Lee KH; Chuang CC; Chen TL; Lai CC; Wu WC
    Eye (Lond); 2014 Sep; 28(9):1080-6; quiz 1087. PubMed ID: 25104736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.
    Mintz-Hittner HA; Geloneck MM; Chuang AZ
    Ophthalmology; 2016 Sep; 123(9):1845-55. PubMed ID: 27241619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
    Freedman SF; Hercinovic A; Wallace DK; Kraker RT; Li Z; Bhatt AR; Boente CS; Crouch ER; Hubbard GB; Rogers DL; VanderVeen D; Yang MB; Cheung NL; Cotter SA; Holmes JM;
    Ophthalmology; 2022 Oct; 129(10):1120-1128. PubMed ID: 35660415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: a Canadian experience.
    Isaac M; Mireskandari K; Fallaha N; Ospina LH; Javidi E; Chorfi S; Superstein R; Hamel P; Tehrani NN
    Can J Ophthalmol; 2023 Dec; 58(6):553-558. PubMed ID: 35940211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review.
    Frosini S; Franco F; Vicini G; Nicolosi C; Varriale G; Dani C; Virgili G; Giansanti F
    J Matern Fetal Neonatal Med; 2022 Sep; 35(17):3337-3342. PubMed ID: 32933350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.
    Isaac M; Tehrani N; Mireskandari K;
    Eye (Lond); 2016 Mar; 30(3):333-41. PubMed ID: 26869159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zone of retinal vascularization and refractive error in premature eyes with and without spontaneously regressed retinopathy of prematurity.
    Dikopf MS; Machen LA; Hallak JA; Chau FY; Kassem IS
    J AAPOS; 2019 Aug; 23(4):211.e1-211.e6. PubMed ID: 31229607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
    Chandra P; Kumawat D; Agarwal D; Chawla R
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?
    Dikci S; Ceylan OM; Demirel S; Yılmaz T
    Arq Bras Oftalmol; 2018; 81(1):12-17. PubMed ID: 29538588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
    Ekinci DY; Çelik K
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP).
    Etezad Razavi M; Shoeibi N; Hassanzadeh S; Kianmehr S; Bakhtiari E
    Strabismus; 2020 Mar; 28(1):49-54. PubMed ID: 31790628
    [No Abstract]   [Full Text] [Related]  

  • 34. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection.
    Milani AE; Arasteh A; Saeedi-Maleki Z; Niyousha MR; Sahebazamani MA; Brumandpur F
    BMC Ophthalmol; 2024 Jun; 24(1):265. PubMed ID: 38907228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RETINAL VASCULAR DEVELOPMENT WITH 0.312 MG INTRAVITREAL BEVACIZUMAB TO TREAT SEVERE POSTERIOR RETINOPATHY OF PREMATURITY: A Longitudinal Fluorescein Angiographic Study.
    Lorenz B; Stieger K; Jäger M; Mais C; Stieger S; Andrassi-Darida M
    Retina; 2017 Jan; 37(1):97-111. PubMed ID: 27454223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
    Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
    Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.
    Laveti V; Balakrishnan D; Rani PK; Mohamed A; Jalali S
    Int Ophthalmol; 2020 Dec; 40(12):3539-3545. PubMed ID: 32776299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity.
    Hoppe C; Holt DG; Arnold BF; Thinda S; Padmanabhan SP; Oatts JT
    J AAPOS; 2022 Dec; 26(6):305.e1-305.e6. PubMed ID: 36265750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.